Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent Granted
Faron has been granted a patent for treatment of Clever-1 positive cancers with bexmarilimab and related structures in the USA. This extends key patent rights around bexmarilimab from an initial 2037 to 2040 in the USA. TURKU, FI / ACCESS Newswire / August 8, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company […]